WallStSmart

Baxter International Inc (BAX)vsMedline Inc. Class A Common Stock (MDLN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 157% more annual revenue ($29.14B vs $11.32B). MDLN leads profitability with a 3.3% profit margin vs -9.7%. MDLN earns a higher WallStSmart Score of 52/100 (C-).

BAX

Buy

51

out of 100

Grade: C-

Growth: 6.0Profit: 3.5Value: 5.7Quality: 6.0
Piotroski: 4/9Altman Z: 1.98

MDLN

Buy

52

out of 100

Grade: C-

Growth: 7.3Profit: 5.0Value: 6.3Quality: 6.8
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BAXUndervalued (+63.1%)

Margin of Safety

+63.1%

Fair Value

$60.34

Current Price

$17.53

$42.81 discount

UndervaluedFair: $60.34Overvalued
MDLNUndervalued (+69.5%)

Margin of Safety

+69.5%

Fair Value

$147.84

Current Price

$39.25

$108.59 discount

UndervaluedFair: $147.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BAX2 strengths · Avg: 10.0/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

EPS GrowthGrowth
237.9%10/10

Earnings expanding 237.9% YoY

MDLN2 strengths · Avg: 9.0/10
EPS GrowthGrowth
1258.0%10/10

Earnings expanding 1258.0% YoY

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

Areas to Watch

BAX4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
2.9%4/10

2.9% revenue growth

Altman Z-ScoreHealth
1.984/10

Grey zone — moderate risk

Debt/EquityHealth
1.603/10

Elevated debt levels

PEG RatioValuation
36.682/10

Expensive relative to growth rate

MDLN3 concerns · Avg: 3.3/10
P/E RatioValuation
36.7x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
6.0%3/10

ROE of 6.0% — below average capital efficiency

Profit MarginProfitability
3.3%3/10

3.3% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : BAX

The strongest argument for BAX centers on Price/Book, EPS Growth.

Bull Case : MDLN

The strongest argument for MDLN centers on EPS Growth, Price/Book. Revenue growth of 10.7% demonstrates continued momentum.

Bear Case : BAX

The primary concerns for BAX are Revenue Growth, Altman Z-Score, Debt/Equity. Debt-to-equity of 1.60 is elevated, increasing financial risk.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 3.3% margins leave little buffer for downturns.

Key Dynamics to Monitor

BAX profiles as a turnaround stock while MDLN is a value play — different risk/reward profiles.

MDLN is growing revenue faster at 10.7% — sustainability is the question.

MDLN generates stronger free cash flow (316M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDLN scores higher overall (52/100 vs 51/100) and 10.7% revenue growth. BAX offers better value entry with a 63.1% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Baxter International Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Baxter International Inc. is an American multinational health care company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions.

Visit Website →

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Want to dig deeper into these stocks?